Product Description
Piclidenoson is an orally bioavailable, adenosine A3 receptor (A3AR) agonist with potential anti-inflammatory activity. Upon administration, piclidenoson selectively targets, binds to and activates the cell surface-expressed A3AR, thereby activating transduction pathways in which A3AR plays a key role.
Mechanisms of Action: ADORA3 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ewopharma AG
Company Location:
Company CEO:
Additional Commercial Interests: Can-Fite BioPharma
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Can-Fite BioPharma presented P3 Psoriasis results on 2024-01-29 for Piclidenoson
Highest Development Phases
Phase 3: Psoriasis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CF101-302PS | P3 |
Not yet recruiting |
Psoriasis |
2027-12-01 |
53% |
2024-10-17 |